Linus S. Lin - Concepedia

Author

Linus S. Lin

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

Linus S Lin, Linus S. Lin

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)United States Military Academy Albany Molecular Research (United States)

About

Linus S. Lin is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, medicine, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	27	961
2	Biochemistry	15	19	749
3	Natural Sciences	11	12	468
4	Engineering	4	4	143
5	Health Sciences	3	3	158

Linus S. Lin

Publications

1.7K

Citations

H-Index

Page 1

	Year	Citations
[<sup>18</sup>F]MK-9470, a positron emission tomography (PET) tracer for<i>in vivo</i>human PET brain imaging of the cannabinoid-1 receptor H. Donald Burns, Koen Van Laere, Sandra Sanabria Bohórquez, Proceedings of the National Academy of Sciences	2007	311
Discovery of <i>N</i>-[(1<i>S</i>,2<i>S</i>)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a Novel, Acyclic Cannabinoid-1 Receptor Inverse Agonist for the Treatment of Obesity Linus S. Lin, Thomas J. Lanza, James P. Jewell, Journal of Medicinal Chemistry Cannabis UseMolecular PharmacologyMedicinal ChemistryCompound 48Biochemistry	2006	122
Antiobesity Efficacy of a Novel Cannabinoid-1 Receptor Inverse Agonist, N-[(1 S,2 S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), in Rodents Tung M. Fong, Xiao-Ming Guan, Donald J. Marsh, Journal of Pharmacology and Experimental Therapeutics	2007	100
Regulation of Energy Homeostasis by Bombesin Receptor Subtype-3: Selective Receptor Agonists for the Treatment of Obesity Xiao-Ming Guan, Howard Chen, Peter H. Dobbelaar, Cell Metabolism ObesityMetabolic SyndromeEnergy HomeostasisMedicinePhysiology	2010	87
Addressing the metabolic activation potential of new leads in drug discovery: a case study using ion trap mass spectrometry and tritium labeling techniques Koppara Samuel, Wenji Yin, Ralph A. Stearns, Journal of Mass Spectrometry Hit IdentificationMetabolic ActivationMetabolomic ProfilingLead IdentificationNew Drug	2003	77
A facile microwave-assisted palladium-catalyzed cyanation of aryl chlorides Harry R. Chobanian, Brett P. Fors, Linus S. Lin Tetrahedron Letters Aryl ChloridesOrganometallic CatalysisCatalysisChemistryMicrowave Synthesis	2006	75
Discovery of MK-5046, a Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of Obesity Iyassu K. Sebhat, Christopher S. Franklin, Michael M.‐C. Lo, ACS Medicinal Chemistry Letters ObesityCompound 22BiochemistryFunctional SelectivityMedicine	2010	65
Discovery of MK-7725, A Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of Obesity Harry R. Chobanian, Yan Guo, Ping Liu, ACS Medicinal Chemistry Letters	2012	61
The discovery of sulfonylated dipeptides as Potent VLA-4 antagonists William K. Hagmann, Philippe L. Durette, Thomas J. Lanza, Bioorganic & Medicinal Chemistry Letters BiochemistryMedicineNatural SciencesMechanism Of ActionPharmacological Agent	2001	59
Antiobesity Effect of MK-5046, a Novel Bombesin Receptor Subtype-3 Agonist Xiao-Ming Guan, Joseph M. Metzger, Liming Yang, Journal of Pharmacology and Experimental Therapeutics	2010	49

Page 1